Risk stratification of latent tuberculosis defined by combined interferon gamma release assays

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Corbière, Véronique ^a   Pottier, Gaelle ^a   Bonkain, Florence ^b   Schepers, Kinda ^b   Verscheure, Virginie ^a   Lecher, Sophie ^c,d,e,f   Doherty, T Mark ^g,h   Locht, Camille ^c,d,e,f   Mascart, Françoise ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c INSERM   (France)

^d CNRS   (France)

^e UNIV LILLE   (France)

^f INSERM U1019   (France)

^g STATENS SERUM INSTITUT   (Denmark)

^h GLAXOSMITHKLINE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPARIN BINDING HEMAGGLUTININ; MYCOBACTERIUM ANTIGEN; RECOMBINANT EARLY SECRETED ANTIGEN TARGET 6; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DYNAMICS; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; INTERFERON GAMMA RELEASE ASSAY; KINETICS; LATENT TUBERCULOSIS; MALE; RETROSPECTIVE STUDY;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; LECTINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84865104047     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043285     Document Type: Article

References (34)

1. Dye C, Williams BG, (2010) The population dynamics and control of tuberculosis. Science 328: 856-861.
2. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, et al (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845-855.
3. Wilkinson D, (2000) Drugs for preventing tuberculosis in HIV infected persons. Cochrane Database Syst Rev 4: CD000171.
4. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, et al. (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36: 1185-1206.
5. Cengiz K, (1996) Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron 73: 421-424.
6. Chou KJ, Fang HC, Bai KJ, Hwang SJ, Yang WC, et al. (2001) Tuberculosis in maintenance dialysis patients. Nephron 88: 138-143.
7. Segall L, Covic A, (2010) Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol 5: 1114-1122.
8. Moore DA, Lightstone L, Javid B, Friedland JS, (2002) High rates of tuberculosis in end-stage renal failure: the impact of international migration. Emerging Infect Dis 8: 77-78.
9. Lawn SD, Wood R, Wilkinson RJ, (2011) Changing Concepts of "Latent Tuberculosis Infection" in Patients Living with HIV Infection. Clin Dev Immunol (2011): doi: 10.1155/2011/980594.
10. Young DB, Gideon HP, Wilkinson RJ, (2009) Eliminating latent tuberculosis. Trends Microbiol 17: 183-188.
11. Pai M, Zwerling A, (2008) Menzies (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149: 177-184.
12. Hougardy JM, Schepers K, Place S, Drowart A, Lechevin V, et al. (2007) Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS ONE 2: e926.
13. Leyten EMS, Arend SM, Prins C, Cobelens FGJ, Ottenhoff THM, et al. (2007) Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol 14: 880-885.
14. Goletti D, Butera O, Vanini V, Lauria FN, Lange C, et al. (2010) Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respi J 36: 135-142.
15. Pai M, (2010) Spectrum of latent tuberculosis- existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol 8: 242.
16. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, et al. (2012) Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12: 45-55.
17. Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, et al. (2011) Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS ONE 6: e18315.
18. Menozzi FD, Reddy VM, Cayet D, Raze D, Debrie AS, et al. (2006) Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions. Microbes Infect 8: 1-9.
19. Masungi C, Temmerman S, Van Vooren JP, Drowart A, Pethe K, et al. (2002) Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis 185: 513-520.
20. Place S, Verscheure V, de San N, Hougardy JM, Schepers K, et al. (2010) HBHA-specific IFN-{gamma} Synthesis at the Site of Infection during Active Tuberculosis in Humans. Am J Respir Crit Care Med 182: 848-854.
21. Hougardy JM, Place S, Hildebrand M, Drowart A, Debrie AS, et al. (2007) Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med 176: 409-416.
22. Cardona P-J, (2009) A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 37: 80-86.
23. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, et al. (2010) Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375: 1920-1937.
24. Andersen P, Doherty TM, Pai M, Weldingh K, (2007) The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 13: 175-182.
25. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, et al. (2009) LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 33: 956-973.
26. Lin MY, Ottenhoff THM, (2008) Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention. Endocr Metab Immune Disord Drug Targets 8: 15-29.
27. Temmerman S, Pethe K, Parra M, Alonso S, Rouanet C, et al. (2004) Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 10: 935-941.
28. Parra M, Pickett T, Delogu G, Dheenadhayalan V, Debrie AS, et al. (2004) The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 72: 6799-6805.
29. Rouanet C, Debrie AS, Lecher S, Locht C, (2009) Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 11: 995-1001.
30. Rouanet C, Locht C. Boosting BCG to protect against TB, (2010) Expert Rev Respir Med. 4: 339-348.
31. Temmerman ST, Place S, Debrie AS, Locht C, Mascart F, (2005) Effector functions of heparin-binding hemagglutinin-specific CD8+ T lymphocytes in latent human tuberculosis. J Infect Dis 192: 226-232.
32. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A, (2011) Negative and Positive Predictive Value of a Whole-Blood IGRA for Developing Active TB- An Update. Am J Respir Crit Care Med 183: 88-95.
33. Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, et al. (2002) Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 40: 704-706.
34. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, et al. (2011) Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 17: 372-376.